All News

EULAR meeting room

Psoriatic Arthritis: EULAR 2026 Recap

Jack Cush, MD

Years of IL-17 vs. IL-23 debate in PsA finally got tested head-to-head: bimekizumab outperformed risankizumab on joint outcomes in the BE BOLD trial, while a GLP-1 combination study suggests weight and metabolic status are active drivers of PsA — not just comorbidities. This recap also digs into early signals that biologic choice may influence whether psoriasis progresses to PsA, and why some well-controlled patients are still in pain.

Read Article
RheumNow Podcast square

Seronegative RA Disease Activity (7.17.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and Gout features from this past week on RheumNow.com.

Read Article
WashDC4.jpg

ACR: Medicare Cuts for Physicians Highlight Need for Reform

ACR

The American College of Rheumatology (ACR) was disappointed that the proposed Medicare Physician Fee Schedule (MPFS) from the Centers for Medicare & Medicaid Services (CMS) once again included a serious cut to the conversion factor.

Read Article
kidneys

The Marriage between Gout and the Kidney

Richard J. Johnson, MD

While the link between uric acid and gout was first described by Alfred Baring Garrod in the 1800s, the proof that uric acid might actually be the cause had to await the self-experimentation of two rheumatologists from the University of Pennsylvania. Given some comments that the presence of urate crystals in synovial fluid might just be a bystander phenomenon, they decided to inject monosodium urate crystals in one knee and water in the other, and both suffered severe attacks of gout in the urate crystal injected knee.

Read Article
vitamins.png

ACP Position Paper on Dietary Supplements

Jack Cush, MD

More than half of U.S. adults use dietary supplements, yet only a quarter use supplements recommended by a healthcare professional, and current law lets supplements reach the market with no premarket safety evaluation, unlike drugs or food additives.

Read Article
many heads

Gout in Minority Populations

Hyon K. Choi, MD, DrPH

Gout is the most common inflammatory arthritis, but its burden is not shared equally across populations. Recent research has revealed substantial racial and ethnic disparities in both who develops gout and the care patients receive. These differences reflect not only genetic susceptibility but also the substantial influence of social determinants of health, healthcare access, and environmental exposures.

Read Article
Why Do Gout Flares Start at Night? The striking propensity for gout flares to initiate at night has been recognized for centuries. More recent epidemiological research supports this observation, indicating that the risk of a gout flare is more than twice as high in the early https://t.co/FbCUmXEl2y
Dr. John Cush RheumNow ( View Tweet)
Rheumatoid arthritis is found in 2-3.8% of gout patients. For more gout content, follow our Gout: More than Flares campaign at https://t.co/lQoiFjubZJ, https://t.co/moAOVUJjKZ

Links:

Dr. John Cush RheumNow ( View Tweet)
Guidelines to Spot Cancer in High Risk Dermatomyositis International guidelines can help identify dermatomyositis patients with a particularly high risk for cancer, according to a retrospective single-center U.S. study. https://t.co/h4jFi2Ph1M https://t.co/BueumKCYHY

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic: Allopurinol for All Gout? Not Quite Dr. Brian Jaros, Chicago, discusses the use of allopurinol. https://t.co/XENBDqZ2Z6 https://t.co/KFTZwuYVLI

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic: When There's Doubt in Gout Dr. Eric Dein discusses how imaging was used in correctly diagnosing a mid-foot symptom in gout. https://t.co/FNI6rlOz1O https://t.co/Xpw98DiEvs

Links:

Dr. John Cush RheumNow ( View Tweet)
Gout Imaging in Care Gout is all about the crystals and the consequences of the disease are due to the inflammation they cause. Getting rid of urate crystals is the ultimate goal in gout, as we now know that it leads to the risk zero of flares and it normalizes the https://t.co/DGuiTOtQFa
Dr. John Cush RheumNow ( View Tweet)
Saliva and Uric Acid Testing A recent report from China reaffirms the potential utility of salivary uric acid (UA) testing delivers smartphone-guided, enzyme-free gout screening at home for pennies per test. https://t.co/VtvJuPNEWA https://t.co/pdBmy5JoQd

Links:

Dr. John Cush RheumNow ( View Tweet)
Four Things About Allopurinol Hypersensitivity Syndrome Dr. Robert Terkeltaub discusses allopurinol hypersensitivity syndrome in gout patients. https://t.co/5seiyfVLW1 https://t.co/0A1Rtk9hzS

Links:

Dr. John Cush RheumNow ( View Tweet)
Genicular artery embolization for knee OA does not work in a 12-mos randomized sham-controlled trial of 58 pts. Pain scores improved equally in both groups https://t.co/7wwmzpTaNL https://t.co/8MsRXqKDo2

Links:

Dr. John Cush RheumNow ( View Tweet)
ARTIC trial enrolled 234 DMARD naive RA (<2yrs) pts; 15.4% (36) were seronegative (SNRA). @enrollment SNRA worse than SPRA(+) w/ higher SJC (17 vs 8, p<0.001), DAS28 (3.9 vs 3.4, p=0.03), US scores (55 vs 25, p<0.001), MD global (49 vs 39, p=0.006). No diff in Sharp score, https://t.co/xDxQKY8ZG2
Dr. John Cush RheumNow ( View Tweet)
Intl consortium (10 EU countries) of 3952 RA pts, 184 MACE events seen 1985-2012. MACE risk signif assoc w/ DAS28 (HR 1.18;1.03-1.35), but NOT RF (HR 1.26; 0.82 to 1.94) or ACPA (HR 1.25; 0.85 to 1.83). RA activity assoc w/ MACE seen in seronegative and double positive https://t.co/RGO5IAM5oL
Dr. John Cush RheumNow ( View Tweet)
Glucocorticoid use in 1st yr of 574 newly DX RA cases-- 75% recv GC in 1st yr; 313 (55%) Rx at 1st visit. (m GC dose =9.3 mg/day. 1/2 (47%) recv IA GC injx. 20% had 1st yr infx. Risk of infx was NS (RR 1.13; 0.77 to 1.67) for 0-10 mg/d vs no GC https://t.co/s9YaGZsUjr https://t.co/ESHvVK1Egx

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 31 studies (14,548 pts) looked at infection in idiopathic inflamm myopathy (IIMs). Infection prevalence was 24%, primarily Respiratory tract. PJP, aspergillosis, H zoster most prevalent pathogens. Risk factors: older age, male, DM, HTN,MDA5+ (OR 3.41), rapidly https://t.co/Go51MUOQlG
Dr. John Cush RheumNow ( View Tweet)
Congratulations to Dr. Chandra Mohan and Univ. of Houston for receiving a $4 million NIH grant for a 10-year longitudinal study to identify the earliest biological triggers of autoimmune disease https://t.co/6kMcv9PD5r https://t.co/CsY8QAxrXR

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×